Scholarlink

<p>Inflammation and immune mediators exacerbate COVID-19; turmeric and ginger possess antiviral and anti-inflammatory properties that may mitigate this response. This study compared the effects of turmeric and ginger on inflammatory markers in patients with COVID-19. This triple-blind randomized clinical trial enrolled 144 COVID-19 outpatients at Kowsar Hospital (Semnan, Iran) in 2021. Participants were randomly allocated to group C (turmeric), group G (ginger), or group P (placebo) using blocked randomization and consumed three 500&#xa0;mg tablets daily for five days (15 tablets total). Inflammatory markers—lactate dehydrogenase (LDH), C-reactive protein (CRP), white blood cell count (WBC), and erythrocyte sedimentation rate (ESR)—were measured at baseline and on day 6. LDH and WBC levels did not differ significantly among groups (p = 0.349 and p = 0.663, respectively). Changes in CRP and ESR varied significantly across groups (p &lt; 0.001), with greater reductions observed in the turmeric and ginger groups compared to the placebo group (p &lt; 0.001), and no difference between the turmeric and ginger groups (CRP: p = 0.263; ESR: p &gt; 0.99). Turmeric and ginger exerted equivalent anti-inflammatory effects; therefore, either agent may serve as a complementary therapy alongside standard treatment to reduce CRP and ESR in COVID-19 outpatients. Trial registration Iranian Registry of Clinical Trials, Trial No IRCT20120109008665N14. Registered 31/08/2021. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Triple-blind randomized controlled trial on the effects of turmeric versus ginger on inflammatory biomarkers in patients with COVID-19

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Zahra Saleh,
  • Mohammad Reza Asgari,
  • Raheb Ghorbani,
  • Hassan Babamohamadi

摘要

Inflammation and immune mediators exacerbate COVID-19; turmeric and ginger possess antiviral and anti-inflammatory properties that may mitigate this response. This study compared the effects of turmeric and ginger on inflammatory markers in patients with COVID-19. This triple-blind randomized clinical trial enrolled 144 COVID-19 outpatients at Kowsar Hospital (Semnan, Iran) in 2021. Participants were randomly allocated to group C (turmeric), group G (ginger), or group P (placebo) using blocked randomization and consumed three 500 mg tablets daily for five days (15 tablets total). Inflammatory markers—lactate dehydrogenase (LDH), C-reactive protein (CRP), white blood cell count (WBC), and erythrocyte sedimentation rate (ESR)—were measured at baseline and on day 6. LDH and WBC levels did not differ significantly among groups (p = 0.349 and p = 0.663, respectively). Changes in CRP and ESR varied significantly across groups (p < 0.001), with greater reductions observed in the turmeric and ginger groups compared to the placebo group (p < 0.001), and no difference between the turmeric and ginger groups (CRP: p = 0.263; ESR: p > 0.99). Turmeric and ginger exerted equivalent anti-inflammatory effects; therefore, either agent may serve as a complementary therapy alongside standard treatment to reduce CRP and ESR in COVID-19 outpatients. Trial registration Iranian Registry of Clinical Trials, Trial No IRCT20120109008665N14. Registered 31/08/2021.